Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jul;63(7):797–803. doi: 10.1136/ard.2003.014050

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial

H Capell 1, R Madhok 1, J Hunter 1, D Porter 1, E Morrison 1, J Larkin 1, E Thomson 1, R Hampson 1, F Poon 1
PMCID: PMC1755058  PMID: 15194574

Abstract

Background: Evidence for disease modifying activity of low dose corticosteroid treatment in rheumatoid arthritis is contradictory. Studies showing radiological benefit suggest that continued treatment is required to sustain the effect.

Objective: To evaluate the effect of low dose oral prednisolone in early rheumatoid arthritis on disease activity over two years.

Design: Double blind placebo controlled trial.

Methods: Patients with rheumatoid arthritis, duration <3 years (n = 167), were started on a disease modifying antirheumatic drug (DMARD; sulphasalazine) and allocated by stratified randomisation to prednisolone 7 mg/day or placebo. Primary outcome measure was radiological damage, assessed by the modified Sharp method. Clinical benefit was a secondary outcome. A proactive approach to identifying and treating corticosteroid adverse events was adopted. Patients who discontinued sulphasalazine were offered an alternative DMARD.

Results: 90 of 257 patients eligible for the study refused to participate (more women than men). Of those enrolled, 84% were seropositive for rheumatoid factor, median age 56 years, median disease duration 12 months, female to male ratio 1.8:1. Prednisolone was given to 84 patients; of these 73% continued prednisolone and 70% sulphasalazine at 2 years. Of the 83 patients on placebo, 80% continued placebo and 64% sulphasalazine at 2 years. There were no significant differences in radiological score or clinical and laboratory measures at 0 and 2 years.

Conclusions: Low dose prednisolone conferred no radiological or clinical benefit on patients maintained on a DMARD over two years. Low dose corticosteroids have no role in the routine management of rheumatoid arthritis treated with conventional disease modifying drugs.

Full Text

The Full Text of this article is available as a PDF (187.0 KB).

Figure 1.

Figure 1

Open in a new tab

 Flow of participants through the WOSERACT study. FU, follow up; pred, prednisolone; SASP, sulphasalazine

Figure 2.

Figure 2

Open in a new tab

 Changes in total x ray score over two years. FWP, F W Poon (radiologist), chronological scoring; JH, J A Hunter (rheumatologist), random scoring.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Boers M. The case for corticosteroids in the treatment of early rheumatoid arthritis. Rheumatology (Oxford) 1999 Feb;38(2):95–97. doi: 10.1093/rheumatology/38.2.95. [DOI] [PubMed] [Google Scholar]
  3. Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., van Zeben D., Dijkmans B. A., Peeters A. J., Jacobs P. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–318. doi: 10.1016/S0140-6736(97)01300-7. [DOI] [PubMed] [Google Scholar]
  4. Bukhari M., Lunt M., Harrison B. J., Scott D. G. I., Symmons D. P. M., Silman A. J. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. 2002 Apr;46(4):906–912. doi: 10.1002/art.10167. [DOI] [PubMed] [Google Scholar]
  5. Corkill M. M., Kirkham B. W., Chikanza I. C., Gibson T., Panayi G. S. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol. 1990 Aug;29(4):274–279. doi: 10.1093/rheumatology/29.4.274. [DOI] [PubMed] [Google Scholar]
  6. Crilly A., Maiden N., Capell H. A., Madhok R. Genotyping for disease associated HLA DR beta 1 alleles and the need for early joint surgery in rheumatoid arthritis: a quantitative evaluation. Ann Rheum Dis. 1999 Feb;58(2):114–117. doi: 10.1136/ard.58.2.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fries J. F., Spitz P. W., Young D. Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982 Sep-Oct;9(5):789–793. [PubMed] [Google Scholar]
  8. Gudbjornsson B., Juliusson U. I., Gudjonsson F. V. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002 Jan;61(1):32–36. doi: 10.1136/ard.61.1.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hansen M., Podenphant J., Florescu A., Stoltenberg M., Borch A., Kluger E., Sørensen S. F., Hansen T. M. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999 Nov;58(11):713–718. doi: 10.1136/ard.58.11.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hench P. S., Kendall E. C., Slocumb C. H., Polley H. F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis. 1949 Jun;8(2):97–104. doi: 10.1136/ard.8.2.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hickling P., Jacoby R. K., Kirwan J. R. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998 Sep;37(9):930–936. doi: 10.1093/rheumatology/37.9.930. [DOI] [PubMed] [Google Scholar]
  12. Jansen L. M., van der Horst-Bruinsma I. E., van Schaardenburg D., Bezemer P. D., Dijkmans B. A. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis. 2001 Oct;60(10):924–927. doi: 10.1136/ard.60.10.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kirwan J. R., Reeback J. S. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol. 1986 May;25(2):206–209. doi: 10.1093/rheumatology/25.2.206. [DOI] [PubMed] [Google Scholar]
  14. Kirwan J. R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995 Jul 20;333(3):142–146. doi: 10.1056/NEJM199507203330302. [DOI] [PubMed] [Google Scholar]
  15. Larsen A., Dale K., Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977 Jul;18(4):481–491. doi: 10.1177/028418517701800415. [DOI] [PubMed] [Google Scholar]
  16. Morrison E., Capell H. A. Corticosteroids in rheumatoid arthritis--the case against. Rheumatology (Oxford) 1999 Feb;38(2):97–100. doi: 10.1093/rheumatology/38.2.97. [DOI] [PubMed] [Google Scholar]
  17. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  18. Saag K. G. Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Rheum. 2001 Oct;45(5):468–471. doi: 10.1002/1529-0131(200110)45:5<468::aid-art367>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  19. Smolen J. S., Kalden J. R., Scott D. L., Rozman B., Kvien T. K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999 Jan 23;353(9149):259–266. doi: 10.1016/s0140-6736(98)09403-3. [DOI] [PubMed] [Google Scholar]
  20. Taves D. R. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443–453. doi: 10.1002/cpt1974155443. [DOI] [PubMed] [Google Scholar]
  21. Treasure T., MacRae K. D. Minimisation: the platinum standard for trials?. Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ. 1998 Aug 8;317(7155):362–363. doi: 10.1136/bmj.317.7155.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wolfe F., Mitchell D. M., Sibley J. T., Fries J. F., Bloch D. A., Williams C. A., Spitz P. W., Haga M., Kleinheksel S. M., Cathey M. A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481–494. doi: 10.1002/art.1780370408. [DOI] [PubMed] [Google Scholar]
  23. de Nijs R. N., Jacobs J. W., Bijlsma J. W., Lems W. F., Laan R. F., Houben H. H., ter Borg E. J., Huisman A. M., Bruyn G. A., van Oijen P. L. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2001 Dec;40(12):1375–1383. doi: 10.1093/rheumatology/40.12.1375. [DOI] [PubMed] [Google Scholar]
  24. van Everdingen Amalia A., Jacobs Johannes W. G., Siewertsz Van Reesema Dirk R., Bijlsma Johannes W. J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 1;136(1):1–12. doi: 10.7326/0003-4819-136-1-200201010-00006. [DOI] [PubMed] [Google Scholar]
  25. van Gestel A. M., Laan R. F., Haagsma C. J., van de Putte L. B., van Riel P. L. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol. 1995 Apr;34(4):347–351. doi: 10.1093/rheumatology/34.4.347. [DOI] [PubMed] [Google Scholar]
  26. van der Heijde D. M. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol. 1996 Aug;10(3):435–453. doi: 10.1016/s0950-3579(96)80043-4. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES